tbuckley/cabot-search huggingface dataset:
Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States
Authors: Krishna P. Reddy, Chung Yin Kong, Emily P. Hyle, Travis P. Baggett, Mingshu Huang, Robert A. Parker, A. David Paltiel, Elena Losina, Milton C. Weinstein, Kenneth A. Freedberg, Rochelle P. Walensky
Journal: JAMA Internal Medicine (2017)

Lung cancer has become a leading cause of death among people living with human immunodeficiency virus (HIV) (PLWH). Over 40% of PLWH in the United States smoke cigarettes; HIV independently increases the risk of lung cancer.
AB0893 Disease related knowledge in gout patients and the relationship with adherence to urate-lowering therapy in east china
Authors: R Yin, T Fu, Q Zhang, L Zhang, L Li, Z Gu
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Gout is a chronic rheumatic disease caused by deposition of monosodium urate crystals in and around the joint, with a reported prevalence of 1.1% in mainland China and 6.24% in Taiwan, making it the most common form of inflammatory arthritis. With the disease progression, gout can cause permanent joint destruction, bone erosion, and organ damage. Urate-lowering therapy (ULT) is necessary to lower and maintain serum urate (sUA) levels at a therapeutic target of &lt;360 μmol/L as this is associated with fewer gout flares, reduction of tophus size, and depletion of urate crystal stores in synovial tissues, making gout the only chronic arthritis that can be "cured". Disease related knowledge of gout patients should be assessed before attempting to improve health education.To date, except one study from south China, all other published papers about gout knowledge and medication adherence are from other countries. To our knowledge, there is no survey from east China. <h3>Objectives</h3> The current study aimed to investigate knowledge related to gout and it9s risk factors, and the relationship with adherence to urate-lowering therapy in patients with gout in east China. <h3>Methods</h3> A cross-sectional study of 229 gout patients recruited from the Affiliated Hospital of Nantong University between August 2015 and November 2016 was conducted with two questionnaire, Gout Knowledge Questionnaire (GKQ) and Compliance Questionnaire on Rheumatology (CQR). Chi-square analysis, t-test, rank sum test, as well as logistic regression analysis were used to analyze data. <h3>Results</h3> 21.5% (49/228) of gout patients in east China had knowledge of gout, and 9.1% (13/143) adhered to ULT. Age, employment, income, alcohol use, family history, acute flares in preceding 1 year, and colchicine use were associated with awareness of gout-related knowledge, and age, income, alcohol use, and colchicine use were the predictors. Among patients with ULT, patients adherent to ULT tended to have gout-related knowledge, compared with non-adherent patients. Awareness of the cause of gout attack, flare prevention induced by ULT and comorbidity were correlated with medication adherence, and the cause of gout attack as well as flare prevention induced by ULT were predictors of adherence to ULT in gout patients in east China. <h3>Conclusions</h3> In this study, 78.5% of patients in east China didn9t have gout-related knowledge. Patients9 knowledge on gout is a significant independent determinant of adherence to ULT. <h3>Acknowledgements</h3> This study was supported by grants from the Cultivative Distinguished Young Scholars Project of Nantong University (2nd);the 2015 Graduate Innovation Project of Nantong University (YKC15075); and College graduate research and innovation of Jiangsu Province (KYZZ15–0353). <h3>Disclosure of Interest</h3> None declared
Nonoperative Treatment of Appendicitis
Authors: William A. Bonadio
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
SAT0048 The pattern of acpa reactivities in anti-ccp positive individuals with non-specific musculoskeletal symptoms at risk of developing ra
Authors: A Hensvold, Y Kisten, V Joshua, M Hansson, L Mathsson-Alm, A Karlsson, H Rezaei, E af Klint, G Fei, A Catrina
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> There is today a paucity of prospective studies to describe the natural longitudinal history of anti-ccp positive individuals developing RA or not developing RA. Further no study to investigate the detailed ACPA reactivities in such a setting is currently available. <h3>Methods</h3> Individuals at risk of developing RA were included in a cohort at Karolinska University Hospital, Stockholm. Examinations of peripheral joints was repeated at one year follow-up visit or at any time the patients experienced worsening of their symptoms. Peripheral blood samples were available at inclusion (n=70). Serum was run on a microarray based on the ImmuoCAP ISAC system testing for ACPA reactivities toward 13 different citrullinated peptides (fillagrin, fibrinogen, alpha-enolase, vimentin, histone) (1). <h3>Results</h3> Individuals referred from primary care with musculoskeletal complaints and positive anti-ccp test were systematically investigated as part of routine care at our rheumatology clinic. Individuals lacking self-reported history of suspect arthritis, clinical arthritis according to rheumatologist and signs of synovitis on ultrasound examination were included in a clinical Risk-RA program with life-style coaching and personalized information on the risk of developing RA. Seventy individuals, with a mean age of 48 years (SD 15) and 86% females, were included in the program. Twenty (29%) individuals developed arthritis during a medium follow up time of 7 months (range 1–25 months). Number of ACPA reactivities at baseline was significant higher among those developing (in mean 6 reactivities) as compared to those not developing arthritis (in mean 4 reactivities). A increased proportion of individuals were showing reactivity towards citrullinated (cit) vimentin (vim) 60–75, fibrinogen (fib) 573 and enolase (eno) (CEP-1) among those developing arthritis (80% for anti-cit-vim 45% for anti-cit-fib and 60% for anti-cit eno) as compared to those not developing arthritis (41% for anti-cit-vim, 30% for anti-cit-fib and 52% for anti-cit-eno). Increased level of anti-cit-vim and anti-cit-eno antibodies was also observed at inclusion for those individuals developing arthritis as compared to those not developing arthritis. <h3>Conclusions</h3> We describe here the pattern of ACPA reactivities in anti-CCP positive individuals with non-specific musculoskeletal symptoms at risk of developing RA and without clinical and ultrasonograph signs of synovitis and report that 30% of these patients will develop arthritis during a short follow-up. Number, frequency and titers of specific ACPA reactivities appear to be enriched already at inclusion among those patients that developed arthritis during follow-up. <h3>References</h3> Hansson et al Arthritis Res Ther 2012. <h3>Disclosure of Interest</h3> None declared
Cardiovascular predictors of death in patients with cirrhosis
Authors: Maurizio Cesari, Anna Chiara Frigo, Marta Tonon, Paolo Angeli
Journal: Hepatology (2017)

Cirrhotic cardiomyopathy is associated with poor outcomes in patients with cirrhosis. We investigated if subclinical cardiac morphologic and functional modifications can influence survival in patients with cirrhosis during follow-up. A series of patients with cirrhosis without cardiovascular or pulmonary disease underwent standard and tissue Doppler echocardiography to assess left ventricular geometry, systolic/diastolic function, and the main haemodynamic parameters. After baseline evaluation 115 patients with cirrhosis were followed up for at least 6 years. During follow-up 54 patients died (47%). On univariate analysis, age, body surface area (BSA), Model for End-Stage Liver Disease (MELD), mean arterial pressure, heart rate, cardiac index, systemic vascular resistance index, and the ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity (E/è) were associated with increased risk of death. In a Cox hazard regression analysis including these factors and other hypothesized important factors (but not MELD), increased age (P = 0.04) and left atrial dimension (P = 0.005) and lower BSA (P = 0.03) were the strongest predictors of death. When MELD was included in the analysis, the main predictors were MELD, age, and BSA. When multivariate analysis was performed incorporating only cardiovascular parameters, increased E/è (P = 0.003) and heart rate (P = 0.03) and reduced mean blood pressure (P = 0.01) were significantly associated with poor prognosis.In a large cohort of patients with cirrhosis and after a long follow-up, MELD, age, and BSA were the main predictors of death; among cardiovascular parameters, left atrium enlargement, increased heart rate and E/è, and reduced mean blood pressure were independent predictors of death. (Hepatology 2018).
Editorial: Ratiometric Optical Imaging of Subclinical Inflammation With a Thrombin‐Cleavable Probe: A Future Tool for the In Vivo Visualization of Clinically Silent Synovitis?
Authors: Katalin Mikecz
Journal: Arthritis & Rheumatology (2017)

It is universally accepted that effective treatment of rheumatoid arthritis (RA) requires initiation of therapy at the early phase of articular inflammation. In addition to clinical and serological assessments, imaging of joint tissues provides useful information for the early diagnosis of RA (1). Although radiographic (X-ray) imaging can be used to detect bone erosions and to monitor disease progression in terms of bone involvement, X-ray does not detect early synovitis.

This article is protected by copyright. All rights reserved.
“I have lost in every facet of my life”: the hidden burden of severe asthma
Authors: Juliet M. Foster, Vanessa M. McDonald, Michael Guo, Helen K. Reddel
Journal: European Respiratory Journal (2017)

People with severe asthma are thought to face a sizeable daily disease burden. This study aimed to explore the little-known life experiences of people living with severe asthma.Adults with severe asthma were invited for telephone interview. Semistructured interviews were conducted until no new themes emerged. The 25 interviews were recorded, transcribed and analysed thematically.Four themes emerged. 1) "The body as a hindrance": severe asthma placed broad limits on life from daily chores to career, relationships and family life that left interviewees feeling emotionally distressed. 2) "Burden of treatment": participants mostly accepted the need to take treatment, but were particularly concerned about side-effects of oral corticosteroids. 3) "Alone with asthma": interviewees felt misunderstood and alone in their experience of breathlessness and frightening exacerbations; practical and emotional support needs were often lacking and the emotional distress of severe asthma was amplified in those with little support. 4) "Striving to adapt": patients used both positive strategies (acquiring self-management skills) and less positive strategies (avoidance of physical exertion) in the process of adjustment to living with severe asthma.Severe asthma imposes long-term, debilitating burdens and should be considered differently to milder disease. There is an urgent need to improve practical and emotional support services for patients and their carers.
Cytokine Inhibition in Patients With Chronic Fatigue Syndrome
Authors: Megan E. Roerink, Jos W.M. Van der Meer
Journal: Annals of Internal Medicine (2017)

Letters19 September 2017Cytokine Inhibition in Patients With Chronic Fatigue SyndromeMegan E. Roerink, MD and Jos W.M. Van der Meer, MD, PhDMegan E. Roerink, MDFrom Radboud University Medical Centre, Nijmegen, the Netherlands.Search for more papers by this author and Jos W.M. Van der Meer, MD, PhDFrom Radboud University Medical Centre, Nijmegen, the Netherlands.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0317 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree that patients with CFS frequently report flu-like symptoms. However, in our experience, the presence of sore throat and tender lymph nodes does not properly discriminate patients with an inflammatory signature from those without. In our study population, 68% of patients regularly had sore throat and 56% regularly had tender lymph nodes, whereas 78% had 1 of these symptoms once. We evaluated treatment effects in subgroups of patients with an infectious onset versus those with a noninfectious start and found no differences between these 2 groups.We also agree that tumor necrosis factor may be involved in ...References1. Netea MG, Kullberg BJ, Vonk AG, Verschueren I, Joosten LA, van der Meer JW. Increased voluntary exercise in mice deficient for tumour necrosis factor-alpha and lymphotoxin-alpha. Eur J Clin Invest. 2007;37:737-41. [PMID: 17696964] CrossrefMedlineGoogle Scholar2. Vallings R. A report from the 5th International AACFS Conference. Phoenix Rising. 6 March 2011. Accessed at http://phoenixrising.me/conferences-2/a-report-from-the-fifth-international-aacfs-conference-by-dr-rosamund-vallings on 29 May 2017. Google Scholar3. Tumor necrosis factor-alpha inhibition in chronic fatigue syndrome. ClinicalTrials.gov: NCT01730495. Accessed at https://clinicaltrials.gov/ct2/show/NCT01730495 on 29 May 2017. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Radboud University Medical Centre, Nijmegen, the Netherlands.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-2391. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCytokine Inhibition in Patients With Chronic Fatigue Syndrome Megan E. Roerink , Sebastian J.H. Bredie , Michael Heijnen , Charles A. Dinarello , Hans Knoop , and Jos W.M. Van der Meer Cytokine Inhibition in Patients With Chronic Fatigue Syndrome Lily Chu Metrics 19 September 2017Volume 167, Issue 6Page: 448KeywordsBrainCentral nervous systemChronic fatigue syndromeCytokinesDisclosureDrugsFatigueLymph nodesPharyngitisTumor necrosis factor ePublished: 19 September 2017 Issue Published: 19 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
AB0452 Case report of allogeneic unrelated-donor mesenchymal stem cells (MSC) infusion in sjogren syndrome (SS) with refractory thrombocytopenia
Authors: J Qi, M Qiu, J Gu
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Intravenous MSC infusion has been reported occasionally in SS treatmen and Immune Thrombocytopenia ttreament. To our knowledge,there is rare report of allogeneic unrelated-donor intravenous MSC infusion in SS with thrombocytopenia without immunosuppresive induction of MSC transplantation. <h3>Objectives</h3> To report the case of a Sjogren syndrome with refractory thrombocytopenia treated with MSC infusion. To review the current literature on intravenous MSC infusion for SS. <h3>Methods</h3> Literature review and multidisciplinary discussion were thoroughly performed before treatment protocol was approved by institutional ethics committee and patient and family signed informed consent form. <h3>Results</h3> A 48 year-old female with a 2-year history of SS, manifested by severe thrombocytopenia (PLT 14–30*10E9/L, after each injection of recombinant human interleukin 11, platelets can be transiently recovered.) refractory to Methylprednisolone, methotrexate, azathioprine and cyclophosphamide received Four infusions (Once a month) of allogeneic unrelated-donor 2x10<sup>6</sup>/Kg MSC. After two infusiong of MSC, the PLT increased gradually to greater than 100*10E9/L. After 1 year of follow-up, Platelet counts remained normal. <h3>Conclusions</h3> These results suggest that mesenchymal stem cells may be a therapeutic strategy for Sjogren syndrome with Refractory thrombocytopenia patients. Larger studies are needed to validate clinical efficacy and safety and to standardize treatment protocol of MSC infusion in SS. <h3>References</h3> Zhang D, Li H, Ma L, et al. The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. Autoimmunity 2014, 47 (8), 519–29. Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood 2012, 120 (15), 3142–51. Wu M, Ge H, Li S, et al. Mesenchymal Stem Cells Immunosuppressed IL-22 in Patients with Immune Thrombocytopenia via Soluble Cellular Factors. Journal of immunology research 2015, 2015, 316351. <h3>Disclosure of Interest</h3> None declared
What it feels like to have a facial disfigurement
Authors: Victoria Wright
Journal: BMJ (2017)

What it feels like to have a facial disfigurementVictoria Wright, 38, lives with an unusual facial appearance.She describes her experiences and the lessons she'd like to pass on Victoria WrightThe first time I realised that I looked different was when a boy called me "fat chin" at primary school.Thirty years later I still remember the burning shame and humiliation.
AB0545 Effect of empathy nursing on the life quality of thepatients with systemic lupus erythematosus
Authors: Y Wen, L Yan, L LiMin
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The patients with Systemic Lupus Erythematosus always had sub-health status in psychology and been troubled by the chronicity of the disease. Empathy nursing is an effective treatment for chronic disease such as cancer or terminal patients. <h3>Objectives</h3> To investigate the effect of empathy nursing on the life quality of patients with Systemic Lupus Erythematosus (SLE). <h3>Methods</h3> 120hospitalized patients with SLE admitted from January 2014 to December 2016 were divided into the control group and the experimental group for 60 people in each randomly. The control group was given routine care and the experimental group was given additional empathy care for 6 months. The World Health Organization Quality of Life (WHOQOL-BREF) Chinese version was evaluated on the 2nd day of hospitalization and 6 months after discharge respectively. <h3>Results</h3> Before intervention, the life quality of the two groups was poor. The scores of the control group and the experimental group in each field had no statistic difference (44.13±16.72 vs 44.08±17.33 in physiology, 51.13±14.38 vs 52.01±13.87 in psychology, 58.12±15.33vs 56.71±8.12in social relation, 54.93±13.2 vs 55.33±11.78 in environment and 52.52±15.6vs 52.03±13.44 overall), (P&gt;0.05). After the intervention, the scores of the WHOQOL-BREF scale in the two groups were improved to different extents (P&lt;0.05) (59.33±13.76 vs 66.77±16.21 in physiology, 57.43±7.88 vs 64.55±11.76 in psychology, 65.22±13.34 vs 72.11±8.12 in social relation and the overall scores were 59.95±14.32 vs 67.89±6.42).The scores of the four dimensions in physiology, psychology, social relations and environment were significantly different from those before the intervention (P&lt;0.05). The improvement of the scores in physiology, psychology, social relations in the experimental group was more obvious than the control group (P&lt;0.05). <h3>Conclusions</h3> Empathy nursing can obviously improve the life quality of SLE patients, and it is worthy to be popularized. <h3>References</h3> Empathy - can it be taught? Jeffrey D, Downie R.J R Coll Physicians Edinb. 2016 Jun;46(2):107–112. Communication Needs of Patients with Breast Cancer: A Qualitative Study. Khoshnazar TA, Rassouli M, Akbari ME, Lotfi-Kashani F, Momenzadeh S, Rejeh N, Mohseny M. Indian J Palliat Care. 2016 Oct-Dec;22(4):402–409. <h3>Disclosure of Interest</h3> None declared
SAT0264 Valvulopathy and pulmonary hypertension in a series of patients with antiphospholipid syndrome
Authors: A Robles, MJ Núñez, E Rodríguez-Castellano, C Busca, JJ Ríos, A Noblejas, F Arnalich, E Martínez
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> To evaluate the prevalence of cardiac valvular involvement and pulmonary arterial hypertension (PAH) and predictive risk factors in a cohort of patients with antiphospholipid antibodies. <h3>Methods</h3> We included 232 patients from our cohort who underwent an echocardiogram. A total of 84 (36%) patients with primary antiphospholipid syndrome (PFS), 47 (20%) with APS secondary to systemic lupus erythematosus (SLE), 47 (20%) patients with antiphospholipid antibodies 23%) with SLE without AAF. The determinations of AAF and lupus anticoagulant were performed according to the indications of the international thrombosis society. Statistical analysis was performed with SPSS 18; using the Chi square test and the Fisher exact test. <h3>Results</h3> In patients with AAF, the echocardiogram was pathological in 88 patients (52%) (p=0.023). Valvular affectation was evidenced in 64 (38%) (p=0.005) and PAH in 16 (p = ns). Seventeen patients (35%), SAF (48%), SAFS (26%), AIF silent (14%) and 9 patients in the non-AAF group (12%) presented with valvular affectation (p=0.002). PAH presented 19 patients, 9 with SAFP (47%), 6 in the SAFS group (32%), 1 in the silent AAF group (5%) and 3 in the non-AAF group (16%) (p= ). Both PAH and valvular involvement were asymptomatic in most cases, although two patients required valvular replacement. The most frequently affected valve in all groups was mitral valve (84%), except in patients with PAH where the most prevalent valvular pathology was tricuspid insufficiency. Patients with valvulopathy and APS had a higher prevalence of total thrombosis than SAF without valvulopathy (p=0.05). Patients with valvulopathy also significantly increased stroke and thrombocytopenia (p=0.04). Patients with valvulopathy had lupus anticoagulant more frequently (p=0.04), with no difference for the rest of AAF. <h3>Conclusions</h3> Subclinical valvular involvement is very common in patients with AAF. Every patient with AAA should be given an echocardiogram in the initial protocol of their study in order to rule out both significant valvulopathy and PAH that can modify the management of the condition. <h3>Disclosure of Interest</h3> None declared